Literature DB >> 11687862

Gibbs memorial lecture. Unifying hypothesis of body fluid volume regulation: implications for cardiac failure and cirrhosis.

R W Schrier1, T Ecder.   

Abstract

Body fluid volume regulation is critically important in maintaining life. In this paper, we review our unifying hypothesis of body fluid volume regulation, which maintains arterial circulatory integrity in health and disease. The integrity of the arterial circulation, as determined by cardiac output and peripheral vascular resistance, is the predominant determinant of renal sodium and water retention. Arterial circulatory integrity can be disturbed either by a decrease in cardiac output, as in low-output cardiac failure, or by a decrease in peripheral vascular resistance, as in high-output states such as high-output cardiac failure and cirrhosis. The resulting arterial underfilling is sensed by baroreceptors that are located in the left ventricle, the aortic arch, the carotid sinus and the renal afferent arterioles. Decreased activation of these receptors during arterial underfilling leads to neurohumoral compensatory responses, which include the stimulation of the sympathetic nervous system, activation of the renin-angiotensin-aldosterone system (RAAS) and the non-osmotic release of vasopressin. These compensatory responses maintain arterial circulatory integrity by increasing peripheral and renal arterial vascular resistance together with renal sodium and water retention. However, over the long term, these adaptive responses may have detrimental effects, such as pulmonary congestion, increased myocardial demand, increased cardiac afterload, ascites and hyponatremia. The intensity of the neurohumoral responses correlates with the progression and severity of both cardiac failure and cirrhosis. The understanding of the pathogenesis of sodium and water retention in cardiac failure and cirrhosis has led to therapies that favorably affect the morbidity and mortality of these patients.

Entities:  

Mesh:

Year:  2001        PMID: 11687862

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN: 0027-2507


  10 in total

1.  What have we learned about loop diuretics in acute decompensated heart failure? The DOSE trial.

Authors:  Dmitry Shchekochikhin; JoAnn Lindenfeld
Journal:  Curr Cardiol Rep       Date:  2012-06       Impact factor: 2.931

Review 2.  Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects.

Authors:  Søren Møller; Jens H Henriksen; Flemming Bendtsen
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 3.  Hyponatremia in acute decompensated heart failure: mechanisms, prognosis, and treatment options.

Authors:  Geoffrey T Jao; Jun R Chiong
Journal:  Clin Cardiol       Date:  2010-11       Impact factor: 2.882

Review 4.  Cardiopulmonary complications in chronic liver disease.

Authors:  Soren Moller; Jens H Henriksen
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

Review 5.  Therapeutic potential of vasopressin receptor antagonists.

Authors:  Farhan Ali; Maya Guglin; Peter Vaitkevicius; Jalal K Ghali
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.

Authors:  Matthew Griffin; Veena S Rao; Juan Ivey-Miranda; James Fleming; Devin Mahoney; Christopher Maulion; Nisha Suda; Krishmita Siwakoti; Tariq Ahmad; Daniel Jacoby; Ralph Riello; Lavanya Bellumkonda; Zachary Cox; Sean Collins; Sangchoon Jeon; Jeffrey M Turner; F Perry Wilson; Javed Butler; Silvio E Inzucchi; Jeffrey M Testani
Journal:  Circulation       Date:  2020-05-15       Impact factor: 29.690

7.  Systemic vascular resistance and fluid status in patients with decompensated liver cirrhosis with or without functional renal failure in Egypt.

Authors:  Ashraf Abd El-Khalik Barakat; Fatma Mohammad Nasr; Amna Ahmed Metwaly; Maged El-Ghannam
Journal:  Electron Physician       Date:  2015-08-10

8.  Cardiac function in patients with early cirrhosis during maximal beta-adrenergic drive: a dobutamine stress study.

Authors:  Aleksander Krag; Flemming Bendtsen; Emilie Kristine Dahl; Andreas Kjær; Claus Leth Petersen; Søren Møller
Journal:  PLoS One       Date:  2014-10-03       Impact factor: 3.240

Review 9.  Nocturia in Parkinson's Disease: Why Does It Occur and How to Manage?

Authors:  Amit Batla; Véronique Phé; Lorenzo De Min; Jalesh N Panicker
Journal:  Mov Disord Clin Pract       Date:  2016-06-07

10.  Vaptans: A new option in the management of hyponatremia.

Authors:  Suruchi Aditya; Aditya Rattan
Journal:  Int J Appl Basic Med Res       Date:  2012-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.